$13.10
-0.55-4.03%
Last update: Nov 12, 4:32 PM
Mesoblast Ltd (MESO) Stock Price, Quote, News & History
MESONASDAQ
Mesoblast finished patient dosing in its Phase 3 trial for a cellular back pain treatment, targeting a market worth over $10 billion.
You can purchase shares of Mesoblast (NASDAQ:MESO) through any online brokerage.
Other companies in Mesoblast’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Mesoblast has a consensus price target of $25.50.
The stock price for Mesoblast (NASDAQ: MESO) is $13.49 last updated November 12, 2026 at 4:32 PM EST.
There are no upcoming dividends for Mesoblast.
Mesoblast does not have any upcoming earnings scheduled.
There is no upcoming split for Mesoblast.
Mesoblast is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is...
